Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report

BACKGROUND: Nintedanib is a tyrosine kinase inhibitor that efficiently slows the progression of idiopathic pulmonary fibrosis (IPF) and has an acceptable tolerability profile. In contrast, immune checkpoint inhibitors (ICIs) such as programmed death 1 and programmed death ligand 1 inhibitors have sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamakawa, Hideaki, Oba, Tomohiro, Ohta, Hiroki, Tsukahara, Yuta, Kida, Gen, Tsumiyama, Emiri, Nishizawa, Tomotaka, Kawabe, Rie, Sato, Shintaro, Akasaka, Keiichi, Amano, Masako, Kuwano, Kazuyoshi, Matsushima, Hidekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704625/
https://www.ncbi.nlm.nih.gov/pubmed/31438923
http://dx.doi.org/10.1186/s12890-019-0920-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704625/
https://www.ncbi.nlm.nih.gov/pubmed/31438923
http://dx.doi.org/10.1186/s12890-019-0920-9

Ejemplares similares